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Our objective was to determine whether oral etoposide and cisplatin combination (EoP) is superior to paclitaxel in the treatment of
advanced breast cancer (ABC) patients pretreated with anthracyclines. From December 1997 to August 2003, 201 patients were
randomised, 100 to EoP and 101 to paclitaxel arms. Four patients in each arm were ineligible. The doses of etoposide and cisplatin
were 50mg p.o. twice a day for 7 days and 70mgm
 2 intravenously (i.v.) on day 1, respectively, and it was 175mgm
 2 on day 1 for
paclitaxel. Both treatments were repeated every 3 weeks. A median of four cycles of study treatment was given in both arms. The
response rate obtained in the EoP arm was significantly higher (36.3 vs 22.2%; P¼0.038). Median response duration was longer for
the EoP arm (7 vs 4 months) (P¼0.132). Also, time to progression was significantly in favour of the EoP arm (5.5 vs 3.9 months;
P¼0.003). Median overall survival was again significantly longer in the EoP arm (14 vs 9.5 months; P¼0.039). Toxicity profile of both
groups was similar. Two patients in each arm were lost due to febrile neutropenia. The observed activity and acceptable toxicity of
EoP endorses the employment of this combination in the treatment of ABC following anthracyclines.
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Survival in breast cancer is improving, mostly related to early
diagnosis. However, at least 40% of the early cases present with
recurrent disease following curative surgery7adjuvant systemic
therapy. Although hormonal treatment is preferred for advanced
breast cancer (ABC), chemotherapy (CT) is required for hormone
receptor-negative and hormone refractory disease.
Anthracycline combinations have been commonly used to treat
for ABC for a long time. Recently, taxanes became the standard
treatment for these patients following anthracycline failure. In
randomised trials, docetaxel (Taxotere
s) was found comparable to
5-fluorouracilþvinorelbine (FUN) and more active than mitomy-
cin Cþvinblastine (MV), and methotrexateþ5-fluororacil (MF)
in this group of patients (Nabholtz et al, 1999; Sjo ¨stro ¨m et al, 1999;
Bonneterre et al, 2002). However, there are limited numbers of
randomised trials comparing the efficacy of paclitaxel to other
drugs or combination CTs in anthracycline-pretreated patients. In
a small phase II randomised trial, capecitabine was found to be as
effective as paclitaxel in patients with ABC pretreated with
anthracyclines (Talbot et al, 2002). Recently, given as a single
agent, docetaxel was reported to be more active than paclitaxel in
terms of overall response rates, time to progression (TTP) and
survival in patients with ABC pretreated with anthracyclines
(Ravdin et al, 2003).
Another active but less popular treatment in anthracycline-
pretreated patients with ABC is etoposideþcisplatin (EoP). A
higher response rate than that achieved with CMF was observed by
giving EP as first-line treatment in a small randomised trial
(Cocconi et al, 1991). Etoposideþcisplatin was also found as an
active treatment for ABC following anthracyclines in the several
phase II trials (Cox et al, 1989; Krook et al, 1990; Icli et al, 1992;
Remick et al, 1996). Furthermore, 42 and 50% response rates with
acceptable side effects were reported by prolonged administration
of oral EoP in two phase II trials, which were higher than those
obtained by giving paclitaxel in ABC patients pretreated with
anthracyclines (Icli and Demirkazik, 1998; Fried et al, 2000). Cost
of the drugs in EoP is much lower than taxanes.
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sWith the premise that EoP may be more effective than paclitaxel,
Turkish Oncology Group (TOG) decided to compare the efficacy of
EoP with paclitaxel in anthracyline-pretreated patients with ABC in
a phase III randomised trial.
PATIENTS AND METHODS
Patients
After obtaining written informed consent, patients with histologi-
cally or cytologically confirmed locally advanced or metastatic
breast cancer were randomised if they meet the following criteria:
measurable or evaluable disease (metastases to skin, pleura and
peritoneum), age 18–70 years, performance status 2 or less
according to WHO criteria, pretreatment with anthracyclines,
negative hormone receptors or hormone refractory disease,
adequate bone marrow reserve measured as neutrophil count
X2 10
9l
 1 and platelet count X100 10
9l
 1, normal BUN,
serum creatinine and bilirubin levels and AST and ALT levels o4
times upper normal limits.
Criteria for exclusion were presence of second primary
malignancy or brain metastasis as the only metastatic site. Brain
metastasis well controlled with radiotherapy, in addition to other
sites of metastasis was not an exclusion criterion.
Patients with disease progression while receiving anthracycline-
based CT for ABC, relapse within 6 months following adjuvant
anthracycline-based CT and no response after two or more cycles
of anthracycline-based CT for ABC, or responded to anthracyclines
for ABC or received adjuvant anthracyclines and relapsed after 6
months (total dosage X360mg of doxorubicin or X450mg of
epirubicin) were regarded as anthracycline pretreated.
Study design
This was a prospective randomised nonblinded multicentre phase
III study. No stratification was carried out for prognostic factors or
centers. Patients were centrally randomised to either paclitaxel or
EoP arms. The primary end point was TTP. Secondary end points
were tumor response rate, duration of response and overall
survival (OS).
Treatment
Chemotherapy doses and schedules were as follows. Paclitaxel
175mgm
 2 intravenously (i.v.) on day 1 or etoposide 50mg b.i.d
p.o. daily for 7 daysþcisplatin 70mgm
 2 i.v. on day 1 with
adequate i.v. hydration every 3 weeks. At least two cycles of study
treatment was planned for each patient, unless there was clear
evidence of progression following the first cycle. Crossover was
allowed for patients with progressive disease at any time. Also,
patients with stable disease after at least two cycles of study
treatment could be crossed over at the discretion of the
investigator. Crossover was not mandatory.
Paclitaxel dose was reduced to 135mgm
 2 in case of previous
RT to pelvis and vertebrae or if ALT and/or AST were more than
three times upper normal limits. If grade 3–4 hematological
toxicity was observed in the prior cycle of the treatment, paclitaxel
was reduced to 135mgm
 2 (or 110mgm
 2 if prior dose was
135mgm
 2). Likewise, etoposide was reduced to 50mg p.o. twice a
day for 5 days and cisplatin to 50mgm
 2. Treatment was delayed
if there was grade 2 or more toxicity at the scheduled date of study
treatment.
Assessment and follow-up
Physical examination, complete blood count, liver and renal
function tests, serum CA-15-3, chest X-ray, abdominal ultrasono-
graphy (USG) or computerised tomoraphy were carried out before
the first cycle of study treatment. Thorax computerised tomo-
graphy (CT) was carried out only if lung metastasis was suspected
from the chest X-ray. Physical examination and routine blood tests
were repeated before each cycle of CT. Chest X-ray or thorax CT
was required every 6 weeks during the treatment and every 3
months post-treatment. Likewise, abdominal USG/CT was required
every 6 weeks during the treatment and every 3 months post-
treatment if intra-abdominal metastasis was present. Response to
treatment was evaluated every 6 weeks, unless there was evidence
of progressive disease on physical examination in 3 weeks. The
same assessment method used to determine the disease status at
baseline was used consistently for efficacy evaluation throughout
the study and follow-up. Routine post-treatment follow-up was
every 1–3 months at the discretion of the investigator in case of
lack of any symptoms or signs suggesting progressive disease.
Response to study treatment was assessed according to WHO
criteria. Response rates were evaluated for the actual treatments
patients had received. Responses were reviewed by two indepen-
dent experts to confirm the response status blindly for treatment
received. Response duration was measured from the date of
response to date of progression. Time to progression was the
duration between the first day of study treatment and date of
progression. Likewise OS was accepted as the time interval
between the first day of study treatment and date of death. Overall
survival was calculated on intent-to-treat basis.
Statistical considerations
A total of 146 events were planned based on the log-rank test, for a
median TTP ratio of 1.65, for two-sided 0.05 type 1 error rates and
0.80 power. Comparisons between the response rates, patient
characteristics and adverse events were carried out by using w
2 test.
Time to progression and OS parameters were analysed using the
Kaplan–Meier method and log-rank test. Stepwise Cox’s regres-
sion analysis was used to assess the significant predictors for
survival. Time interval from diagnosis and relapse to study
treatment, CT, relative dose intensity (RDI), number of metastatic
sites and age were used as continuous variables and type of study
treatment as a dichotomous variable.
RESULTS
Patient characteristics
Between December 1997 and August 2002, 201 patients from seven
Oncology centres in Turkey were enrolled. A total of 100 patients
were randomised to EoP arm and 101 to paclitaxel arm.
Randomisation was carried out centrally by the data centre of
TOG. Four patients in each arm were ineligible because one patient
in each arm had poor performance status and were lost before the
start of study treatment, three patients in the EoP and two in the
paclitaxel arms withdrew their consents and one patient in the
paclitaxel arm was injured in a car accident and the treatment
could never be started. Thus, there were 96 eligible patients in the
EoP arm and 97 in the paclitaxel arm. Patient characteristics
including prior treatments are depicted in Table 1. There were no
substantial differences between the two arms. There were two
evaluable patients, one in paclitaxel and one in EoP arms, who had
cytologically proven metastatic disease of pleura with effusion. All
other patients had measurable disease. The median number of
treatment cycles were 4 (ranges 1–8) for both arms. In total, 68
patients in the EoP and 75 patients in the paclitaxel arm received
three to six cycles of treatment. Only four and seven patients in the
EoP and paclitaxel arms, respectively, were given one cycle of
treatment. Relative dose intensities were 85.17 and 85.74% for the
etoposide and cisplatin, respectively, vs 89.27% for the paclitaxel.
While paclitaxel dosage was reduced in five patients (5%), EP was
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pelvis.
Efficacy
A total of 91 patients in the EoP arm and 95 in the paclitaxel arm
were evaluable for response. One patient was given paclitaxel
instead of assigned EoP and was excluded from response
evaluation. However, her survival duration was included in the
EoP arm on intent-to-treat basis. Two patients in the EoP arm and
three in the paclitaxel arm died before any response evaluation.
Likewise, two patients in the EoP arm did not come for further
treatment following the first cycle. Response to study treatment is
shown in Table 2. Total response rates were 36.3 and 22.2% in the
EoP and paclitaxel arms, respectively (P¼0.038). Complete
response was achieved in three patients in each arm.
Five out of 42 patients (11.9%) crossed over to EoP from
paclitaxel vs two out of 30 patients (6.7%) crossed over to
paclitaxel achieved a PR. Until July 2003, disease progression was
observed in 182 patients and 165 had died.
The duration of response was not significantly different between
the two arms (Table 2). Median response duration for patients in
the EoP and paclitaxel arms was 7 and 4 months, respectively (P:
0.132). Time to progression was significantly in favour of the EoP
arm (P: 0.003). Median TTP was 5.5 months for the EoP arm and
3.9 months for the paclitaxel arm (Figure 1). Likewise, median
survival for patients in the EoP arm (14 month) was longer than
those in the paclitaxel arm (9.5 months) (P¼0.039) (Figure 2). The
1-year survival rate was also in favour of the EoP arm, although
the difference was not statistically significant (55.3 vs 40.7%;
P¼0.168).
Although not significant, overall response rates were in favour of
EoP arm in patients who had adjuvant anthracyclines more than 6
months ago and those who were resistant to prior anthracyclines
for metastatic disease or relapsed within 6 months of adjuvant
anthracyclines when compared to paclitaxel arm (36.8 vs 33.3%
and 23.3 vs 18.8%, respectively). In patients who responded to
prior anthracycline treatment, EoP has yielded a significantly
higher response rate (55.6 vs 17.9%; P¼0.005). While there was no
significant difference in terms of TTP in patients with adjuvant
anthracyclines more than 6 months ago (5.071.0 vs 4.670.5
months; P¼0.611), it was significantly higher in favour of EoP arm
in anthracycline-responsive or -resistant patients (4.571.1 vs
3.071.1 months, P¼0.005; 6.071.0 vs 3.570.3 months,
P¼0.006).
Multivariate analysis including time interval from diagnosis and
relapse to study treatment, CT, RDI, number of metastatic sites,
age and type of study treatment showed that only type of study
treatment had significant impact on survival (P¼0.0281). The only
other parameter that was found to have an impact on OS in
multivariate analysis close to statistical significance was the
number of metastatic sites (P¼0.059).
Table 1 Patient characteristics
EoP (n¼96) Paclitaxel (n¼97) P-value
Median age (years) (range) 47 (26–69) 49 (24–70) 0.377
Performance status (WHO)
02 0 1 7
1 50 45 0.401
22 6 3 5
Site of metastasis
Locally advanced 4 3
Skin 47 37 0.148
Lymph node 22 15
Lung 47 47
Liver 35 46 0.145
Bone 45 39 0.385
Brain 3 3
Peritoneum 5 2
Number of metastatic sites
12 9 2 9
2 33 44 0.354
3 or more 34 24
Hormone receptor
ER/PR+ 29 31
ER/PR  15 22 0.298
Unknown 52 44
Oncogene expression
HER2+ 11 11
HER2  9 13 0.763
Unknown 76 73
TIDTR 28.475.0 28.973.9 0.350
Prior treatments
Surgery 72 72 1.000
Radiotherapy 0.285
Adjuvant 17 17
Metastatic 18 11
Hormone 0.158
Adjuvant 10 18
Metastatic 14 16
Prior anthracyclines
a 0.663
13 3 3 2
22 4
31 8 1 3
44 3 4 8
Setting of study drugs 0.947
First line 18 20
Second line 59 58
Third line 19 19
EoP: cisplation+oral etoposide; WHO¼World Health Organization; TIDTR: time
from initial diagnosis to treatment.
a1: disease progression while receiving
anthracycline-based CT for ABC; 2: relapse within 6 months following adjuvant
anthracycline-based CT; 3: no response after two or more cycles of anthracycline-
based CT for ABC; 4: responded to anthracyclines for ABC or received adjuvant
anthracyclines and relapsed after 6 months (total dosage X360mg of doxorubicin or
X450mg of epirubicin). ER¼oestrogen receptor; PR¼progesterone receptor;
HER2¼c-ErbB-2.
Table 2 Results of the response evaluation and time-related variables
EoP (n¼91) T (n¼94) P-value
Response type (%)
OR 33 (36.3) 21 (22.3) 0.038
CR 3 (3.3) 3 (3.2)
PR 30 (33.0) 18 (19.1)
Stable 44 (48.3) 53 (56.4)
Progression 14 (15.4) 20 (21.3)
Paclitaxel EoP:
42 patients
EoP paclitaxel:
30 patients
Crossover
PR 5 (11.9) 2 (6.7)
Response duration
(95% CI)
7.071.1 (4.9–9.1) 4.070.5 (3.0–4.9) 0.132
TTP (95% CI) 5.570.9 (3.7–7.3) 3.970.3 (3.4–4.4) 0.0035
OS (95% CI) 14.071.2 (11.7–16.3) 9.571.0 (7.4–11.5) 0.039
1-Year survival rate
(%)
55.375.1 40.775.0 0.048
EoP¼etoposideplus cisplatin; TTP¼time to progression; CI¼confidence interval.
OR¼overall response; CR¼complete response; PR¼partial response.
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Chemotherapy toxicity is shown in Table 3. Complete blood counts
were required every 3 weeks unless a febrile episode occurred.
Therefore, the nadirs for neutrophils and platelets between the
treatment cycles were not assessed adequately. Grade 4 haemato-
logic toxicities were observed in four and six patients in the EP and
paclitaxel arms, respectively. Delay of study treatment for at least 1
week due to myelosuppression occurred in 21 patients in the EoP
group vs in three patients in the paclitaxel group. Likewise, 23 and
17 patients had delayed treatments from other causes in the EoP
and paclitaxel groups, respectively. Two patients in each arm were
lost probably related to treatment toxicity. The causes of deaths
were febrile neutropenia. Also, one patient was lost with fulminant
hepatitis 4 weeks after the first dose of paclitaxel. Grade 3 nausea
was more common in the EoP arm (15 patients). On the other
hand, there were few patients with grade 3 arthralgia and
neurologic toxicity in the paclitaxel arm. Likewise, three patients
in the paclitaxel arm suffered from congestive heart failure while
taking study treatment.
DISCUSSION
This is the first randomised trial comparing the efficacy of
paclitaxel with other CT in anthracycline-pretreated patients with
breast cancer. In this trial, EoP was found to have higher efficacy in
terms of response rates, TTP and OS when compared to paclitaxel.
The additive and synergistic effects of cisplatin and etoposide in
experimental models have been reported previously (Burchenal
et al, 1979; Mabel and Little, 1981). Although EP has been
commonly employed in lung cancer and germ cell tumors, it is not
a well-established treatment for patients with breast cancer.
Nevertheless, cisplatin was found to be an active drug in breast
cancer in 1980s (Sledge and Roth, 1989). However, early trials with
single agent i.v. etoposide in previously treated patients with ABC
were not promising (Sledge, 1991).
The efficacy of EP was assessed in eight phase 2 trials including
260 patients previously treated for ABC (Athanassiades et al, 1986;
Cocconi et al, 1986; Giaccone et al, 1988; Cox et al, 1989; Krook
et al, 1990; Icli et al, 1992; Ceci et al, 1995; Remick et al, 1996). A
total response rate of 26.8% was obtained by giving etoposide 100–
130mgm
 2 i.v. for 3–5 days and cisplatin 60–100mgm
 2 i.v.
every 3 weeks to these heavily pretreated patients. The highest rate
of grade 3–4 leukopenia was 31% in one trial, and altogether four
toxic deaths were reported in these trials.
Following the emergence of oral etoposide, the role of prolonged
oral etoposide in the treatment of breast cancer was investigated in
five phase II trials (Calvert et al, 1993; Martin et al, 1994; Palombo
et al, 1994; Atienza et al, 1995; Bontenbal et al, 1995). Unlike the
results of single agent i.v. etoposide, the overall response rate was
23.8% in 143 patients with ABC, most of whom were pretreated.
Etoposide was utilised 50–100mg p.o. for 14–21 days every 3–4
weeks in these trials. Myelosuppression, more prominent with 21
days of etoposide, and alopecia were notable toxicities in these
trials.
So far, only two phase II trials looked into the role of oral EoP in
ABC (Icli and Demirkazik, 1998; Fried et al, 2000). In our phase II
trial, we have used the same dosage and schedule of EoP as in the
present study. Out of 35 (42.8%) heavily pretreated patients, 15
responded. Median response duration and OS were 6 and 8
months, respectively. Grade 3 leukopenia was observed in 14.3% of
the patients and only one patient had grade 4 anaemia.
A lower dosage of cisplatin (50mgm
 2) and longer duration of
oral etoposide (50mgm
 2 for 17 days) were utilised in the second
trial by Fried et al. In 26 patients previously exposed to
anthracyclines, 50% response rate with 7 months of response
duration has been reported (Fried et al, 2000). Four patients (15%)
required hospitalisation for neutropenic fever in that trial. The
response rate achieved in the present randomised study (36.3%) is
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Figure 1 Kaplan–Meier curves for TTP according to the assigned arms.
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Figure 2 Kaplan–Meier curves for OS according to the assigned arms.
Table 3 Summary of common toxicities
EoP (n¼96) T (n¼97)
Grade 3 Grade 4 Grade 3 Grade 4
Haematological
Anaemia 3 0 0 0
Neutropenia 14 4
a 56
b
Thrombocytopenia 1 0 1 1
Nausea 15 0 1 0
Arthralgia 0 0 3 0
Neurologic 0 0 1 0
Cardiac 1
c 03
d 0
Toxic death 2 3
aOne patient had febrile neutropenia.
bTwo patients had febrile neutropenia.
cSupraventricular tachycardia.
dCongestive heart failure.
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Likewise, the 22.2% response rate obtained in the paclitaxel arm is
comparable with those achieved in previous trials employing
175mgm
 2 i.v. paclitaxel every 3 weeks in anthracycline-
pretreated patients (Abrams et al, 1995). Both results of the past
phase 2 trials and present randomised trial are in favour of EoP
when compared to paclitaxel. On the other hand, myelotoxicity of
EoP was somewhat higher than that of paclitaxel (18 vs 11% grade
3–4 toxicity). Likewise, more patients in the EoP arm had delayed
treatment interval due to toxicity. One might argue that the
efficacy of paclitaxel could be increased by employing higher and
more myelotoxic dosages. However, a randomised trial failed to
show any favourable effect of higher than 175mgm
 2 of paclitaxel
every 3 weeks in ABC, which excludes such an explanation of the
lower efficacy of paclitaxel when compared to EoP in our trial
(Winer et al, 2004).
Also, it was gratifying to see that both TTP and OS were
significantly higher in the EoP arm when compared to paclitaxel
arm, which has not been usual for randomised CT trials involving
patients with ABC. Both TTP and OS curves show a stable progress
in favour of the EoP arm (Figures 1 and 2). Although there were
some minor differences in terms of patient characteristics between
the two groups, they had no significant impact on TTP and OS in
multivariate analysis. Moreover, there were no notable differences
between the groups in terms of prior treatments and setting of
study treatments, which rule out the role of these factors on the
favourable results of EoP arm.
The myelotoxicity, however, was higher in the EoP arm when
compared to T. In all, 21 patients in the EoP arm vs only three
patients in the paclitaxel arm had at least 7 days of treatment
delays due to myelosuppression. Likewise, nausea and asthenia
were more common in the EoP arm. Probably more myelotoxicity
in each arm would be noted if CBCs were repeated weekly instead
of every 3 weeks. Two deaths in each arm following febrile
neutropenia also suggest that the grade 4 neutropenia was more
common than noticed for both EoP and paclitaxel arms.
Toxicities observed in several phase II as well as in two
randomised trials assessing the efficacy of EP in breast cancer
have limited the use of this combination in breast cancer
(Giaccone et al, 1988; Krook et al, 1990; Cocconi et al, 1991;
Remick et al, 1996; Icli et al, 2001). However, the dosage of
cisplatin in all these trials was higher when compared to the
present trial (100 vs 70mgm
 2). A randomised phase 2 study
comparing low (60mgm
 2) vs high (100mgm
 2) doses of
cisplatin in the EP combination against breast cancer concluded
that the dose of cisplatin had no significant effect in terms of TTP
and OS (Ceci et al, 1995). Also, the dose intensity of both cisplatin
and etoposide in the present trial was found to have no significant
impact on both TTP and OAS in the multivariate analysis.
Therefore, it may be premised that similar efficacy could be
achieved by lower and less toxic dosages of both cisplatin and oral
etoposide in ABC.
In the 1990s, paclitaxel 175mgm
 2 i.v. every 3 weeks was
considered as the treatment of choice following anthracyclines for
patients with ABC (Nabholtz et al, 1996). Our randomised trial of
EoP vs paclitaxel proves that EoP is more active in this group of
patients. Significantly improved survival in the EoP arm in this
trial is a rarely observed phenomenon in randomised trials of ABC
treatment. Approximately 10 times lower price of EoP than
paclitaxel also favours this treatment, especially in countries with
limited sources of health expenditure. However, we should admit
that absence of quality of life assessment is the weaknesses of the
present trial.
In conclusion, results obtained in the present trial supports the
use of EoP in the treatment of ABC. Further randomised trials will
enlighten the efficacy of this relatively old treatment when
compared to the new active drugs in breast cancer. Likewise, it
will be interesting to see the efficacy of this treatment combined
with herceptin in HER2-positive patients.
ACKNOWLEDGEMENTS
We thank the following members of the Turkish Oncology
Group for their active participation: Adnan Aydiner (Istanbul),
Gulistan Bulutlar (Istanbul), Dilek Dincol (Ankara), Abdurrahman
Isikdogan (Diyarbakir), Halil Kavgaci (Trabzon), Feyyaz Ozdemir
(Trabzon), Mustafa Samur (Antalya) and Yavuz Ozisik (Ankara).
We also thank Nuran Caglayan for her help in data processing.
REFERENCES
Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N,
Desmond-Hellmann S, Canetta R, Friedman MA (1995) Paclitaxel activity
in heavily pretreated breast cancer: a National Cancer Institute referral
center. J Clin Oncol 13: 2056–2065
Athanassiades P, Bacoyiannes H, Kontoyiannes D (1986) Etoposide and
cisdichlorodiammine platinum in advanced breast carcinoma resistant to
previous chemotherapy. Chemioterapia 5: 125–127
Atienza DM, Vogel CL, Trock B, Swain SM (1995) Phase II study of
oral etoposide for patients with advanced breast cancer. Cancer 12:
2485–2490
Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P,
Assadourian S (2002) Docetaxel vs 5-fluorouracil plus vinorelbine in
metastatic breast cancer after anthracycline therapy failure. Br J Cancer
87: 1210–1215
Bontenbal M, Planting AS, Verweij J, de Wit R, Kruit WH, Stoter G, Klijn JG
(1995) Second-line chemotherapy with long-term low-dose oral etopo-
side in patients with advanced breast cancer. Breast Cancer Res Treat 34:
185–189
Burchenal JH, Kalaher K, Dew K, Lokys L (1979) Rationale for development
of platinum analogs. Cancer Treat Rep 63: 1493–1498
Calvert AH, Lind MJ, Millward MM, Cantwell BM, Gumbrell L,
Proctor M, Simmons D, Chapman F, Robinson A, Charlton C
(1993) Long-term oral etoposide in metastatic breast cancer:
clinical and pharmacokinetic results. Cancer Treat Rev 19(Suppl C):
27–33
Ceci G, Bisagni G, Cocconi G, Rodino C, Belsanti V, Bertusi M, Buzzi F,
Bacchi M (1995) Cisplatin and VP-16 in metastatic breast carcinoma as
third line chemotherapy: a randomised study comparing low vs high
dose of cisplatin. Tumori 81: 241–244
Cocconi G, Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G, Colozza MA,
De Lisi V, Lottici R, Mosconi AM (1991) Cisplatin and etoposide as first-
line chemotherapy for metastatic breast carcinoma: a prospective
randomized trial of the Italian Oncology Group for Clinical Research. J
Clin Oncol 9: 664–669
Cocconi G, Tonato M, Dicostanzo F, Bisagni G, Belsanti V, Buzzi F, Ceci G
(1986) Platinum and etoposide in chemotherapy refractory metastatic
breast cancer. A phase II trial of the Italian Oncology Group for Clinical
Research (GOIRC). Eur J Clin Oncol 22: 761–764
Cox EB, Burton GV, Olsen GA, Vugrin D (1989) Cisplatin and etoposide: an
effective treatment for refractory breast carcinoma. Am J Clin Oncol 12:
53–56
Fried G, Stein ME, Haim N (2000) Clinical activity of cisplatin and
prolonged oral administration of etoposide in previously treated,
anthracycline-resistant, metastatic breast cancer patients: a phase II
study. Med Ped Oncol 34: 10–13
Giaccone G, Donadio M, Ferrati P, Calciati A (1988) Cisplatin and
etoposide in chemotherapy–refractory advanced breast cancer. Tumori
74: 191–193
Icli F, Akbulut H, Dinc¸ol D, Onur H, Demirkazik A, Cam R, Cay F, Demirci
S, Uner A, Erekul S (2001) A randomized trial of four cycles of adjuvant
Cisplatin and etoposide in advanced breast cancer
F Icli et al
643
British Journal of Cancer (2005) 92(4), 639–644 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sAC (adriamycin+cyclophosphamide)7two cycles of EP (etoposide+
cisplatin) in node positive patients with breast cancer. Ann Oncol 12:
1011–1013
Icli F, Demirkazik A (1998) Cisplatin and oral etoposide (PEO) in heavily
pretreated patients with advanced breast cancer. Proc ASCO 17: 560
(abstr)
Icli F, Gu ¨nel N, Dinc¸ol D, Gunel N, Karaoguz H, Demirkazik A (1992)
Cisplatin plus VP-16 combination chemotherapy in advanced refractory
breast cancer. J Surg Oncol 50: 251–253
Krook JE, Loprinzi CL, Schaid DJ, Kardinal CG, Mailliard JA, Pfeifle DM,
Ellison NM, Reuter NF, Nelimark RA (1990) Evaluation of the
continuous infusion of etoposide plus cisplatin in metastatic breast
cancer. A colloborative North Central Cancer Treatment Group Mayo
Clinic phase II study. Cancer 65: 418–421
Mabel JA, Little AD (1981) Therapeutic synergism in murine tumors for
combination of cisdiammine-dichloroplatinum with VP16-213 or BCNU.
Proc AACR-ASCO 22: 357
Martin M, Lluch A, Casado A, Santabarbara P, Adrover E, Valverde JJ,
Lopez-Martin JA, Rodriguez-Lescure A, Azagra P, Garcia-Conde J (1994)
Clinical activity of chronic oral etoposide in previously treatment
metastatic breast cancer. J Clin Oncol 12: 986–991
Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G,
Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd
B (1996) Multicenter, randomized comparative study of two doses of
paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:
1858–1867
Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J,
Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino
A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY,
Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M,
Aapro M (1999) Prospective randomized trial of docetaxel vs mitomycin
plus vinblastine in patients with metastatic breast cancer progressing
despite previous anthracycline-containing chemotherapy. 304 Study
Group. J Clin Oncol 17: 1413–1424
Palombo H, Estape J, Vinolas N, Grau JJ, Mane JM, Daniels M, Mellado B
(1994) Chronic oral etoposide in advanced breast cancer. Cancer
Chemother Pharmacol 33: 527–529
Ravdin P, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman
L, Sundaram S, Urba W, Olsen S, Meyers ML, Jones S (2003) Phase III
comparison of docetaxel and paclitaxel in patients with metastatic breast
cancer. Eur J Cancer 1(Suppl 5): S201
Remick SC, Chmura M, Drior CT, Sporn J, Healey B, Hilstro J, DeConti RC,
Horton J, Ruckdeschel JC, Harper GR (1996) Concurrent 72h continuous
infusion of etoposide and cisplatin in metastatic breast cancer. Am J Clin
Oncol 19: 125–131
Sjo ¨stro ¨m J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S,
Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere
V, Anderson H, Bergh J (1999) Docetaxel compared with sequential
methotrexate and 5-fluorouracil in patients with advanced breast cancer
after anthracycline failure: a randomised phase III study with crossover
on progression by the Scandinavian Breast Group. Eur J Cancer 35:
1194–1201
Sledge Jr GW (1991) Etoposide in the management of metastatic breast
cancer. Cancer 67: 266–270
Sledge Jr GW, Roth BJ (1989) Cisplatin in the management of breast cancer.
Semin Oncol 16: 110–115
Talbot DC, Moiseyenko V, Van Belle S, O’Reilly SM, Alba Conejo E,
Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S,
Osterwalder B (2002) Randomised, phase II trial comparing oral
capecitabine (Xeloda) with paclitaxel in patients with metastatic/
advanced breast cancer pretreated with anthracyclines. Br J Cancer 86:
1367–1372
Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN,
Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp
SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L (2004)
Failure of higher-dose paclitaxel to improve outcome in patients with
metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin
Oncol 22: 2061–2068
Cisplatin and etoposide in advanced breast cancer
F Icli et al
644
British Journal of Cancer (2005) 92(4), 639–644 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s